MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12-09

AUTHORS

María Luz Morales, Alicia Arenas, Alejandra Ortiz-Ruiz, Alejandra Leivas, Inmaculada Rapado, Alba Rodríguez-García, Nerea Castro, Ivana Zagorac, Miguel Quintela-Fandino, Gonzalo Gómez-López, Miguel Gallardo, Rosa Ayala, María Linares, Joaquín Martínez-López

ABSTRACT

FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited when used in monotherapy due to the emergence of drug-resistance. Thus, a better understanding of drug-resistance pathways could be a good strategy to explore and evaluate new combinational therapies for AML. Here, we used phosphoproteomics to identify differentially-phosphorylated proteins in patients with AML and TKI resistance. We then studied resistance mechanisms in vitro and evaluated the efficacy and safety of rational combinational therapy in vitro, ex vivo and in vivo in mice. Proteomic and immunohistochemical studies showed the sustained activation of ERK1/2 in bone marrow samples of patients with AML after developing resistance to FLT3 inhibitors, which was identified as a common resistance pathway. We examined the concomitant inhibition of MEK-ERK1/2 and FLT3 as a strategy to overcome drug-resistance, finding that the MEK inhibitor trametinib remained potent in TKI-resistant cells and exerted strong synergy when combined with the TKI midostaurin in cells with mutated and wild-type FLT3. Importantly, this combination was not toxic to CD34+ cells from healthy donors, but produced survival improvements in vivo when compared with single therapy groups. Thus, our data point to trametinib plus midostaurin as a potentially beneficial therapy in patients with AML. More... »

PAGES

18630

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41598-019-54901-9

DOI

http://dx.doi.org/10.1038/s41598-019-54901-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1123224106

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31819100


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD34", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Synergism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MAP Kinase Kinase Kinase 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MAP Kinase Signaling System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Staurosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "fms-Like Tyrosine Kinase 3", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morales", 
        "givenName": "Mar\u00eda Luz", 
        "id": "sg:person.011531010113.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011531010113.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arenas", 
        "givenName": "Alicia", 
        "id": "sg:person.01370551766.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370551766.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ortiz-Ruiz", 
        "givenName": "Alejandra", 
        "id": "sg:person.014511315537.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014511315537.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leivas", 
        "givenName": "Alejandra", 
        "id": "sg:person.01372105606.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372105606.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), ISCIII, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.413448.e", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
            "Servicio de Hematolog\u00eda, Hospital 12 de Octubre, Madrid, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), ISCIII, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rapado", 
        "givenName": "Inmaculada", 
        "id": "sg:person.01043176077.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043176077.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodr\u00edguez-Garc\u00eda", 
        "givenName": "Alba", 
        "id": "sg:person.012330222437.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012330222437.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Servicio de Hematolog\u00eda, Hospital 12 de Octubre, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Servicio de Hematolog\u00eda, Hospital 12 de Octubre, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castro", 
        "givenName": "Nerea", 
        "id": "sg:person.01230567471.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230567471.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zagorac", 
        "givenName": "Ivana", 
        "id": "sg:person.012270161561.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012270161561.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quintela-Fandino", 
        "givenName": "Miguel", 
        "id": "sg:person.01367073264.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367073264.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bioinformatics Unit, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "Bioinformatics Unit, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00f3mez-L\u00f3pez", 
        "givenName": "Gonzalo", 
        "id": "sg:person.0700636421.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700636421.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gallardo", 
        "givenName": "Miguel", 
        "id": "sg:person.01314426424.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314426424.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universidad Complutense de Madrid, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.4795.f", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
            "Servicio de Hematolog\u00eda, Hospital 12 de Octubre, Madrid, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), ISCIII, Madrid, Spain", 
            "Universidad Complutense de Madrid, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ayala", 
        "givenName": "Rosa", 
        "id": "sg:person.0577335726.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577335726.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universidad Complutense de Madrid, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.4795.f", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
            "Universidad Complutense de Madrid, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Linares", 
        "givenName": "Mar\u00eda", 
        "id": "sg:person.0610155426.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610155426.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universidad Complutense de Madrid, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.4795.f", 
          "name": [
            "H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre \u2013 Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain", 
            "Servicio de Hematolog\u00eda, Hospital 12 de Octubre, Madrid, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), ISCIII, Madrid, Spain", 
            "Universidad Complutense de Madrid, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mart\u00ednez-L\u00f3pez", 
        "givenName": "Joaqu\u00edn", 
        "id": "sg:person.01267204742.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267204742.34"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11864-017-0456-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084033255", 
          "https://doi.org/10.1007/s11864-017-0456-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2016.41", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008846662", 
          "https://doi.org/10.1038/onc.2016.41"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41408-018-0070-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101635836", 
          "https://doi.org/10.1038/s41408-018-0070-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bcj.2011.43", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006006579", 
          "https://doi.org/10.1038/bcj.2011.43"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-013-1334-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019243333", 
          "https://doi.org/10.1007/s12185-013-1334-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd4281", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012432963", 
          "https://doi.org/10.1038/nrd4281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.3679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013317238", 
          "https://doi.org/10.1038/nm.3679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bcj.2015.19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052608742", 
          "https://doi.org/10.1038/bcj.2015.19"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12943-018-0801-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101066802", 
          "https://doi.org/10.1186/s12943-018-0801-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12-09", 
    "datePublishedReg": "2019-12-09", 
    "description": "FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited when used in monotherapy due to the emergence of drug-resistance. Thus, a better understanding of drug-resistance pathways could be a good strategy to explore and evaluate new combinational therapies for AML. Here, we used phosphoproteomics to identify differentially-phosphorylated proteins in patients with AML and TKI resistance. We then studied resistance mechanisms in vitro and evaluated the efficacy and safety of rational combinational therapy in vitro, ex vivo and in vivo in mice. Proteomic and immunohistochemical studies showed the sustained activation of ERK1/2 in bone marrow samples of patients with AML after developing resistance to FLT3 inhibitors, which was identified as a common resistance pathway. We examined the concomitant inhibition of MEK-ERK1/2 and FLT3 as a strategy to overcome drug-resistance, finding that the MEK inhibitor trametinib remained potent in TKI-resistant cells and exerted strong synergy when combined with the TKI midostaurin in cells with mutated and wild-type FLT3. Importantly, this combination was not toxic to CD34+ cells from healthy donors, but produced survival improvements in vivo when compared with single therapy groups. Thus, our data point to trametinib plus midostaurin as a potentially beneficial therapy in patients with AML.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41598-019-54901-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8098657", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1045337", 
        "issn": [
          "2045-2322"
        ], 
        "name": "Scientific Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "Fms-like tyrosine kinase 3", 
      "acute myeloid leukemia", 
      "tyrosine kinase inhibitors", 
      "myeloid leukemia", 
      "combinational therapy", 
      "kinase inhibitors", 
      "new combinational therapies", 
      "common resistance pathways", 
      "TKI-resistant cells", 
      "MEK inhibitor trametinib", 
      "single therapy group", 
      "bone marrow samples", 
      "tyrosine kinase 3", 
      "wild-type fms-like tyrosine kinase 3", 
      "drug resistance pathways", 
      "survival improvement", 
      "beneficial therapy", 
      "FLT3 inhibitors", 
      "healthy donors", 
      "therapy group", 
      "TKI resistance", 
      "immunohistochemical study", 
      "marrow samples", 
      "ex vivo", 
      "MEK-ERK1/2", 
      "MEK inhibition", 
      "patients", 
      "therapy", 
      "concomitant inhibition", 
      "sustained activation", 
      "trametinib", 
      "midostaurin", 
      "leukemia", 
      "vivo", 
      "inhibitors", 
      "resistance mechanisms", 
      "kinase 3", 
      "resistance pathways", 
      "inhibition", 
      "cells", 
      "monotherapy", 
      "pathway", 
      "CD34", 
      "mice", 
      "strong synergy", 
      "efficacy", 
      "ERK1/2", 
      "best strategy", 
      "vitro", 
      "activation", 
      "safety", 
      "better understanding", 
      "resistance", 
      "group", 
      "donors", 
      "response", 
      "strategies", 
      "protein", 
      "study", 
      "effect", 
      "improvement", 
      "mechanism", 
      "combination", 
      "samples", 
      "key drivers", 
      "synergy", 
      "understanding", 
      "emergence", 
      "phosphoproteomics", 
      "data points", 
      "point", 
      "drivers", 
      "rational combinational therapy", 
      "inhibitor trametinib", 
      "TKI midostaurin"
    ], 
    "name": "MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia", 
    "pagination": "18630", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1123224106"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41598-019-54901-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31819100"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41598-019-54901-9", 
      "https://app.dimensions.ai/details/publication/pub.1123224106"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_831.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41598-019-54901-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-54901-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-54901-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-54901-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-54901-9'


 

This table displays all metadata directly associated to this object as RDF triples.

367 TRIPLES      22 PREDICATES      131 URIs      114 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41598-019-54901-9 schema:about N0e918362a2ed4674b472a8b447ac0f47
2 N1189ec9393ca4547810affffd5946a6a
3 N13392917a427419a9b95871c8fa90d03
4 N1583a1c0165d4720948ade188167b2f2
5 N1acf79933ab84aa98843d810546ad3db
6 N2364db95957b42f9969f304e7b6ea946
7 N2471ac910e364be0ba4a2f89a31185b5
8 N28c4b13ad4644e699d3df740a9d9cbd1
9 N3303d2e998be4944b122109104316534
10 N4344556a0af14d19a1fd9a8d01ec0463
11 N46ea45408ea7403081f68c6b73765d65
12 N4a5f78a25f124883b856f46138054f3b
13 N5396c6cd37c44cb9b1036782de905b86
14 N62c3add3dd52426399533e8f11a51151
15 N6a57e525e8174f03919eb7271e0da32b
16 N802e7cbd6ff34ba69a8427a30d21940e
17 N87ed8c9e196d4c958742315a8bec4c4b
18 N90c96a269f334ce78242ff3067f92125
19 Nc7f00a555c7d41528a88d38ed92b59ba
20 Nca0a8610f2be4bfc9b1134d3e92d2e98
21 Ncffc0ad6a8e5467ab107d25a59b98659
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N3683f558761b49e88a85b1f41dd6dc8a
25 schema:citation sg:pub.10.1007/s11864-017-0456-2
26 sg:pub.10.1007/s12185-013-1334-8
27 sg:pub.10.1038/bcj.2011.43
28 sg:pub.10.1038/bcj.2015.19
29 sg:pub.10.1038/nm.3679
30 sg:pub.10.1038/nrd4281
31 sg:pub.10.1038/onc.2016.41
32 sg:pub.10.1038/s41408-018-0070-y
33 sg:pub.10.1186/s12943-018-0801-5
34 schema:datePublished 2019-12-09
35 schema:datePublishedReg 2019-12-09
36 schema:description FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited when used in monotherapy due to the emergence of drug-resistance. Thus, a better understanding of drug-resistance pathways could be a good strategy to explore and evaluate new combinational therapies for AML. Here, we used phosphoproteomics to identify differentially-phosphorylated proteins in patients with AML and TKI resistance. We then studied resistance mechanisms in vitro and evaluated the efficacy and safety of rational combinational therapy in vitro, ex vivo and in vivo in mice. Proteomic and immunohistochemical studies showed the sustained activation of ERK1/2 in bone marrow samples of patients with AML after developing resistance to FLT3 inhibitors, which was identified as a common resistance pathway. We examined the concomitant inhibition of MEK-ERK1/2 and FLT3 as a strategy to overcome drug-resistance, finding that the MEK inhibitor trametinib remained potent in TKI-resistant cells and exerted strong synergy when combined with the TKI midostaurin in cells with mutated and wild-type FLT3. Importantly, this combination was not toxic to CD34+ cells from healthy donors, but produced survival improvements in vivo when compared with single therapy groups. Thus, our data point to trametinib plus midostaurin as a potentially beneficial therapy in patients with AML.
37 schema:genre article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N6793896a47ba46c4a916aef0224acbd0
41 Nf61a5ec282ce49728d51df6402497dae
42 sg:journal.1045337
43 schema:keywords CD34
44 ERK1/2
45 FLT3 inhibitors
46 Fms-like tyrosine kinase 3
47 MEK inhibition
48 MEK inhibitor trametinib
49 MEK-ERK1/2
50 TKI midostaurin
51 TKI resistance
52 TKI-resistant cells
53 activation
54 acute myeloid leukemia
55 beneficial therapy
56 best strategy
57 better understanding
58 bone marrow samples
59 cells
60 combination
61 combinational therapy
62 common resistance pathways
63 concomitant inhibition
64 data points
65 donors
66 drivers
67 drug resistance pathways
68 effect
69 efficacy
70 emergence
71 ex vivo
72 group
73 healthy donors
74 immunohistochemical study
75 improvement
76 inhibition
77 inhibitor trametinib
78 inhibitors
79 key drivers
80 kinase 3
81 kinase inhibitors
82 leukemia
83 marrow samples
84 mechanism
85 mice
86 midostaurin
87 monotherapy
88 myeloid leukemia
89 new combinational therapies
90 pathway
91 patients
92 phosphoproteomics
93 point
94 protein
95 rational combinational therapy
96 resistance
97 resistance mechanisms
98 resistance pathways
99 response
100 safety
101 samples
102 single therapy group
103 strategies
104 strong synergy
105 study
106 survival improvement
107 sustained activation
108 synergy
109 therapy
110 therapy group
111 trametinib
112 tyrosine kinase 3
113 tyrosine kinase inhibitors
114 understanding
115 vitro
116 vivo
117 wild-type fms-like tyrosine kinase 3
118 schema:name MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
119 schema:pagination 18630
120 schema:productId N048fb1b14430465583a07c93c347dfaa
121 N3ce1ec7c038d47a5b0238d0e4f5eebdd
122 Ncdb93bd3aca944738b471f470ebdcf12
123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123224106
124 https://doi.org/10.1038/s41598-019-54901-9
125 schema:sdDatePublished 2022-01-01T18:54
126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
127 schema:sdPublisher Ncd91ab12017646dab1ae553a19791c09
128 schema:url https://doi.org/10.1038/s41598-019-54901-9
129 sgo:license sg:explorer/license/
130 sgo:sdDataset articles
131 rdf:type schema:ScholarlyArticle
132 N0310752677ef4a7595c644037df92d3a rdf:first sg:person.0577335726.86
133 rdf:rest Nb27d6e9d20314268a0e0463015dfb84e
134 N048fb1b14430465583a07c93c347dfaa schema:name dimensions_id
135 schema:value pub.1123224106
136 rdf:type schema:PropertyValue
137 N0e918362a2ed4674b472a8b447ac0f47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Protein Kinase Inhibitors
139 rdf:type schema:DefinedTerm
140 N1189ec9393ca4547810affffd5946a6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Leukemia, Myeloid, Acute
142 rdf:type schema:DefinedTerm
143 N13392917a427419a9b95871c8fa90d03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Bone Marrow Cells
145 rdf:type schema:DefinedTerm
146 N156e0c73c0e945e8aa40de5f5c8a338e rdf:first sg:person.012330222437.97
147 rdf:rest N2347987745154823a2263f5005c27bbe
148 N1583a1c0165d4720948ade188167b2f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Mice
150 rdf:type schema:DefinedTerm
151 N1acf79933ab84aa98843d810546ad3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Pyridones
153 rdf:type schema:DefinedTerm
154 N1e61a52616e44cffb968679cb57aa891 rdf:first sg:person.012270161561.99
155 rdf:rest N88104f67820f4cbc9699f5ce81b73e8d
156 N2177c86a698244cea2912bfe94415a1b rdf:first sg:person.01043176077.60
157 rdf:rest N156e0c73c0e945e8aa40de5f5c8a338e
158 N2347987745154823a2263f5005c27bbe rdf:first sg:person.01230567471.29
159 rdf:rest N1e61a52616e44cffb968679cb57aa891
160 N2364db95957b42f9969f304e7b6ea946 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Humans
162 rdf:type schema:DefinedTerm
163 N2471ac910e364be0ba4a2f89a31185b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Pyrimidinones
165 rdf:type schema:DefinedTerm
166 N28c4b13ad4644e699d3df740a9d9cbd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Female
168 rdf:type schema:DefinedTerm
169 N3303d2e998be4944b122109104316534 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Cell Line, Tumor
171 rdf:type schema:DefinedTerm
172 N3683f558761b49e88a85b1f41dd6dc8a rdf:first sg:person.011531010113.29
173 rdf:rest Ncb9f359e62a44bde95b564c61dc33c1a
174 N3ce1ec7c038d47a5b0238d0e4f5eebdd schema:name doi
175 schema:value 10.1038/s41598-019-54901-9
176 rdf:type schema:PropertyValue
177 N4344556a0af14d19a1fd9a8d01ec0463 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Drug Resistance, Neoplasm
179 rdf:type schema:DefinedTerm
180 N46ea45408ea7403081f68c6b73765d65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Drug Synergism
182 rdf:type schema:DefinedTerm
183 N4a213a30fed24f12a223405d64dc8cd2 rdf:first sg:person.014511315537.97
184 rdf:rest Nd2a22e7570414ba7a3ef8810b645a3f2
185 N4a5f78a25f124883b856f46138054f3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Animals
187 rdf:type schema:DefinedTerm
188 N5396c6cd37c44cb9b1036782de905b86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name fms-Like Tyrosine Kinase 3
190 rdf:type schema:DefinedTerm
191 N62c3add3dd52426399533e8f11a51151 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name MAP Kinase Kinase Kinase 1
193 rdf:type schema:DefinedTerm
194 N6793896a47ba46c4a916aef0224acbd0 schema:issueNumber 1
195 rdf:type schema:PublicationIssue
196 N6a57e525e8174f03919eb7271e0da32b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Staurosporine
198 rdf:type schema:DefinedTerm
199 N7129eec654854ba987ddc2a296df8bba rdf:first sg:person.01314426424.46
200 rdf:rest N0310752677ef4a7595c644037df92d3a
201 N802e7cbd6ff34ba69a8427a30d21940e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Aged
203 rdf:type schema:DefinedTerm
204 N87ed8c9e196d4c958742315a8bec4c4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name MAP Kinase Signaling System
206 rdf:type schema:DefinedTerm
207 N88104f67820f4cbc9699f5ce81b73e8d rdf:first sg:person.01367073264.39
208 rdf:rest N9511bcdca8c244998ccb322c5abba95f
209 N90c96a269f334ce78242ff3067f92125 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Male
211 rdf:type schema:DefinedTerm
212 N9511bcdca8c244998ccb322c5abba95f rdf:first sg:person.0700636421.39
213 rdf:rest N7129eec654854ba987ddc2a296df8bba
214 Nb27d6e9d20314268a0e0463015dfb84e rdf:first sg:person.0610155426.87
215 rdf:rest Nf72ca1f7c2aa4cf5af8a1046d56ff034
216 Nc7f00a555c7d41528a88d38ed92b59ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Antigens, CD34
218 rdf:type schema:DefinedTerm
219 Nca0a8610f2be4bfc9b1134d3e92d2e98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Adult
221 rdf:type schema:DefinedTerm
222 Ncb9f359e62a44bde95b564c61dc33c1a rdf:first sg:person.01370551766.38
223 rdf:rest N4a213a30fed24f12a223405d64dc8cd2
224 Ncd91ab12017646dab1ae553a19791c09 schema:name Springer Nature - SN SciGraph project
225 rdf:type schema:Organization
226 Ncdb93bd3aca944738b471f470ebdcf12 schema:name pubmed_id
227 schema:value 31819100
228 rdf:type schema:PropertyValue
229 Ncffc0ad6a8e5467ab107d25a59b98659 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Middle Aged
231 rdf:type schema:DefinedTerm
232 Nd2a22e7570414ba7a3ef8810b645a3f2 rdf:first sg:person.01372105606.62
233 rdf:rest N2177c86a698244cea2912bfe94415a1b
234 Nf61a5ec282ce49728d51df6402497dae schema:volumeNumber 9
235 rdf:type schema:PublicationVolume
236 Nf72ca1f7c2aa4cf5af8a1046d56ff034 rdf:first sg:person.01267204742.34
237 rdf:rest rdf:nil
238 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
239 schema:name Medical and Health Sciences
240 rdf:type schema:DefinedTerm
241 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
242 schema:name Oncology and Carcinogenesis
243 rdf:type schema:DefinedTerm
244 sg:grant.8098657 http://pending.schema.org/fundedItem sg:pub.10.1038/s41598-019-54901-9
245 rdf:type schema:MonetaryGrant
246 sg:journal.1045337 schema:issn 2045-2322
247 schema:name Scientific Reports
248 schema:publisher Springer Nature
249 rdf:type schema:Periodical
250 sg:person.01043176077.60 schema:affiliation grid-institutes:grid.413448.e
251 schema:familyName Rapado
252 schema:givenName Inmaculada
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043176077.60
254 rdf:type schema:Person
255 sg:person.011531010113.29 schema:affiliation grid-institutes:grid.7719.8
256 schema:familyName Morales
257 schema:givenName María Luz
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011531010113.29
259 rdf:type schema:Person
260 sg:person.012270161561.99 schema:affiliation grid-institutes:grid.7719.8
261 schema:familyName Zagorac
262 schema:givenName Ivana
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012270161561.99
264 rdf:type schema:Person
265 sg:person.01230567471.29 schema:affiliation grid-institutes:grid.144756.5
266 schema:familyName Castro
267 schema:givenName Nerea
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230567471.29
269 rdf:type schema:Person
270 sg:person.012330222437.97 schema:affiliation grid-institutes:grid.7719.8
271 schema:familyName Rodríguez-García
272 schema:givenName Alba
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012330222437.97
274 rdf:type schema:Person
275 sg:person.01267204742.34 schema:affiliation grid-institutes:grid.4795.f
276 schema:familyName Martínez-López
277 schema:givenName Joaquín
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267204742.34
279 rdf:type schema:Person
280 sg:person.01314426424.46 schema:affiliation grid-institutes:grid.7719.8
281 schema:familyName Gallardo
282 schema:givenName Miguel
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314426424.46
284 rdf:type schema:Person
285 sg:person.01367073264.39 schema:affiliation grid-institutes:grid.7719.8
286 schema:familyName Quintela-Fandino
287 schema:givenName Miguel
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367073264.39
289 rdf:type schema:Person
290 sg:person.01370551766.38 schema:affiliation grid-institutes:grid.7719.8
291 schema:familyName Arenas
292 schema:givenName Alicia
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370551766.38
294 rdf:type schema:Person
295 sg:person.01372105606.62 schema:affiliation grid-institutes:grid.7719.8
296 schema:familyName Leivas
297 schema:givenName Alejandra
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372105606.62
299 rdf:type schema:Person
300 sg:person.014511315537.97 schema:affiliation grid-institutes:grid.7719.8
301 schema:familyName Ortiz-Ruiz
302 schema:givenName Alejandra
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014511315537.97
304 rdf:type schema:Person
305 sg:person.0577335726.86 schema:affiliation grid-institutes:grid.4795.f
306 schema:familyName Ayala
307 schema:givenName Rosa
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577335726.86
309 rdf:type schema:Person
310 sg:person.0610155426.87 schema:affiliation grid-institutes:grid.4795.f
311 schema:familyName Linares
312 schema:givenName María
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610155426.87
314 rdf:type schema:Person
315 sg:person.0700636421.39 schema:affiliation grid-institutes:grid.7719.8
316 schema:familyName Gómez-López
317 schema:givenName Gonzalo
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700636421.39
319 rdf:type schema:Person
320 sg:pub.10.1007/s11864-017-0456-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084033255
321 https://doi.org/10.1007/s11864-017-0456-2
322 rdf:type schema:CreativeWork
323 sg:pub.10.1007/s12185-013-1334-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019243333
324 https://doi.org/10.1007/s12185-013-1334-8
325 rdf:type schema:CreativeWork
326 sg:pub.10.1038/bcj.2011.43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006006579
327 https://doi.org/10.1038/bcj.2011.43
328 rdf:type schema:CreativeWork
329 sg:pub.10.1038/bcj.2015.19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052608742
330 https://doi.org/10.1038/bcj.2015.19
331 rdf:type schema:CreativeWork
332 sg:pub.10.1038/nm.3679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013317238
333 https://doi.org/10.1038/nm.3679
334 rdf:type schema:CreativeWork
335 sg:pub.10.1038/nrd4281 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012432963
336 https://doi.org/10.1038/nrd4281
337 rdf:type schema:CreativeWork
338 sg:pub.10.1038/onc.2016.41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008846662
339 https://doi.org/10.1038/onc.2016.41
340 rdf:type schema:CreativeWork
341 sg:pub.10.1038/s41408-018-0070-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1101635836
342 https://doi.org/10.1038/s41408-018-0070-y
343 rdf:type schema:CreativeWork
344 sg:pub.10.1186/s12943-018-0801-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101066802
345 https://doi.org/10.1186/s12943-018-0801-5
346 rdf:type schema:CreativeWork
347 grid-institutes:grid.144756.5 schema:alternateName Servicio de Hematología, Hospital 12 de Octubre, Madrid, Spain
348 schema:name Servicio de Hematología, Hospital 12 de Octubre, Madrid, Spain
349 rdf:type schema:Organization
350 grid-institutes:grid.413448.e schema:alternateName Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain
351 schema:name Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain
352 H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre – Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
353 Servicio de Hematología, Hospital 12 de Octubre, Madrid, Spain
354 rdf:type schema:Organization
355 grid-institutes:grid.4795.f schema:alternateName Universidad Complutense de Madrid, Madrid, Spain
356 schema:name Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain
357 H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre – Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
358 Servicio de Hematología, Hospital 12 de Octubre, Madrid, Spain
359 Universidad Complutense de Madrid, Madrid, Spain
360 rdf:type schema:Organization
361 grid-institutes:grid.7719.8 schema:alternateName Bioinformatics Unit, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
362 Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
363 H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre – Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
364 schema:name Bioinformatics Unit, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
365 Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
366 H12O-CNIO Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre – Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
367 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...